Literature DB >> 26561568

ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Rα from the cell surface of leukocytes during inflammatory responses.

Isabell Yan1, Jeanette Schwarz2, Karsten Lücke1, Neele Schumacher2, Valéa Schumacher1, Stefanie Schmidt2, Björn Rabe2, Paul Saftig2, Marjo Donners3, Stefan Rose-John2, Hans-Willi Mittrücker1, Athena Chalaris4.   

Abstract

The cytokine IL-6 is part of a regulatory signaling network that controls immune responses. IL-6 binds either to the membrane-bound IL-6 receptor-α (classic signaling) or to the soluble IL-6 receptor-α (trans-signaling) to initiate signal transduction via gp130 activation. Because classic and trans-signaling of IL-6 fulfill different tasks during immune responses, controlled shedding of the membrane-bound IL-6 receptor-α from the surface of immune cells can be considered a central regulator of IL-6 function. The results from cell culture-based experiments have implicated both a disintegrin and metalloprotease 10 and a disintegrin and metalloprotease 17 in IL-6 receptor-α shedding. However, the nature of the protease mediating IL-6 receptor-α release in vivo is not yet known. We used hypomorphic a disintegrin and metalloprotease 17 mice and conditional a disintegrin and metalloprotease 10 knock-out mice to identify the natural protease of the murine IL-6 receptor-α. Circulating homeostatic soluble IL-6 receptor-α levels are not dependent on a disintegrin and metalloprotease 10 or 17 activity. However, during Listeria monocytogenes infection, IL-6 receptor-α cleavage by the α-secretase a disintegrin and metalloprotease 17 is rapidly induced from the surface of different leukocyte populations. In contrast, CD4-Cre-driven a disintegrin and metalloprotease 10 deletion in T cells did not influence IL-6 receptor-α shedding from these cells after L. monocytogenes infection. A disintegrin and metalloprotease 17 was also required for IL-6 receptor-α ectodomain cleavage and release during endotoxemia. These results demonstrate a novel physiologic role for a disintegrin and metalloprotease 17 in regulating murine IL-6 signals during inflammatory processes. © Society for Leukocyte Biology.

Entities:  

Keywords:  Listeria monocytogenes; Metalloproteases; endotoxin shock; shedding; trans-signalling

Mesh:

Substances:

Year:  2015        PMID: 26561568     DOI: 10.1189/jlb.3A0515-207R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  26 in total

1.  Bacteriocin BacSp222 and Its Succinylated Forms Exhibit Proinflammatory Activities Toward Innate Immune Cells .

Authors:  Justyna Śmiałek; Monika Bzowska; Alicja Hinz; Renata Mężyk-Kopeć; Kamilla Sołtys; Paweł Mak
Journal:  J Inflamm Res       Date:  2022-08-12

Review 2.  Therapeutic Potential of Targeting Regulated Intramembrane Proteolysis Mechanisms of Voltage-Gated Ion Channel Subunits and Cell Adhesion Molecules.

Authors:  Samantha L Hodges; Alexandra A Bouza; Lori L Isom
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

3.  Posttranslational modifications by ADAM10 shape myeloid antigen-presenting cell homeostasis in the splenic marginal zone.

Authors:  Nathalie Diener; Jean-Fred Fontaine; Matthias Klein; Thomas Hieronymus; Florian Wanke; Florian C Kurschus; Andreas Ludwig; Carl Ware; Paul Saftig; Tobias Bopp; Björn E Clausen; Ronald A Backer
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-21       Impact factor: 11.205

Review 4.  Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation.

Authors:  Juliane Lokau; Maria Agthe; Christoph Garbers
Journal:  Mediators Inflamm       Date:  2016-07-14       Impact factor: 4.711

5.  The role of ADAM17 in the T-cell response against bacterial pathogens.

Authors:  Moritz Andreas Link; Karsten Lücke; Joanna Schmid; Valéa Schumacher; Thomas Eden; Stefan Rose-John; Hans-Willi Mittrücker
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

6.  A Role for Soluble IL-6 Receptor in Osteoarthritis.

Authors:  Graham Akeson; Charles J Malemud
Journal:  J Funct Morphol Kinesiol       Date:  2017-08-02

7.  Meprin Metalloproteases Generate Biologically Active Soluble Interleukin-6 Receptor to Induce Trans-Signaling.

Authors:  Philipp Arnold; Inga Boll; Michelle Rothaug; Neele Schumacher; Frederike Schmidt; Rielana Wichert; Janna Schneppenheim; Juliane Lokau; Ute Pickhinke; Tomas Koudelka; Andreas Tholey; Björn Rabe; Jürgen Scheller; Ralph Lucius; Christoph Garbers; Stefan Rose-John; Christoph Becker-Pauly
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

8.  Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma.

Authors:  Kathrin Kaiser; Katja Prystaz; Anna Vikman; Melanie Haffner-Luntzer; Stephanie Bergdolt; Gudrun Strauss; Georg H Waetzig; Stefan Rose-John; Anita Ignatius
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-01       Impact factor: 3.000

9.  ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.

Authors:  Stefanie Schmidt; Neele Schumacher; Jeanette Schwarz; Simone Tangermann; Lukas Kenner; Michaela Schlederer; Maria Sibilia; Markus Linder; Annelore Altendorf-Hofmann; Thomas Knösel; Elisabeth S Gruber; Georg Oberhuber; Julia Bolik; Ateequr Rehman; Anupam Sinha; Juliane Lokau; Philipp Arnold; Anne-Sophie Cabron; Friederike Zunke; Christoph Becker-Pauly; Adele Preaudet; Paul Nguyen; Jennifer Huynh; Shoukat Afshar-Sterle; Ashwini L Chand; Jürgen Westermann; Peter J Dempsey; Christoph Garbers; Dirk Schmidt-Arras; Philip Rosenstiel; Tracy Putoczki; Matthias Ernst; Stefan Rose-John
Journal:  J Exp Med       Date:  2018-02-22       Impact factor: 14.307

10.  Control of Listeria monocytogenes infection requires classical IL-6 signaling in myeloid cells.

Authors:  Karsten Lücke; Isabell Yan; Sonja Krohn; Annika Volmari; Stefanie Klinge; Joanna Schmid; Valéa Schumacher; Oliver M Steinmetz; Stefan Rose-John; Hans-Willi Mittrücker
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.